These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38917793)

  • 21. Trofinetide in Rett syndrome: A brief review of safety and efficacy.
    Singh A; Balasundaram MK; Gupta D
    Intractable Rare Dis Res; 2023 Nov; 12(4):262-266. PubMed ID: 38024580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
    Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model.
    Darwish M; Obianom ON; Youakim JM; Darling I; Lukacova V; Bradley H
    Adv Ther; 2024 Aug; 41(8):3328-3341. PubMed ID: 38963587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trofinetide (Daybue) for Rett syndrome.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):e115-e116. PubMed ID: 38981105
    [No Abstract]   [Full Text] [Related]  

  • 25. Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome.
    Tareen MK; Mohiyuddin Z
    Asian J Psychiatr; 2024 May; 95():104011. PubMed ID: 38555801
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
    Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
    Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
    Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
    Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
    Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized open-label trial of dextromethorphan in Rett syndrome.
    Smith-Hicks CL; Gupta S; Ewen JB; Hong M; Kratz L; Kelley R; Tierney E; Vaurio R; Bibat G; Sanyal A; Yenokyan G; Brereton N; Johnston MV; Naidu S
    Neurology; 2017 Oct; 89(16):1684-1690. PubMed ID: 28931647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
    Ebata S; Yoshizaki A; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Okiyama N; Kodera M; Hasegawa M; Sato S
    Lancet Rheumatol; 2022 Aug; 4(8):e546-e555. PubMed ID: 38294008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
    Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial.
    Freilinger M; Dunkler D; Lanator I; Item CB; Mühl A; Fowler B; Bodamer OA
    J Dev Behav Pediatr; 2011; 32(6):454-60. PubMed ID: 21654506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trofinetide-a new chapter in rett syndrome's treatment.
    Furqan M
    Front Pharmacol; 2023; 14():1284035. PubMed ID: 38035006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.